Interaction between thienopyridines and proton pump inhibitors

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Interactions

Background:

• Adenosine diphosphate (ADP) is critical for thrombus formation, making its inhibition a strategy to prevent cardiovascular events in Acute Coronary Syndrome (ACS) and Percutaneous Coronary Intervention (PCI) patients.
• The P2Y12 receptor, a key target for ADP, is a viable pharmacological target due to its limited tissue distribution.
• Thienopyridines are a class of drugs that irreversibly inhibit the P2Y12 receptor, often used with aspirin.

Purpose of the Study:

• To provide an overview of the pharmacokinetic and pharmacodynamic properties of thienopyridine drugs.
• To critically discuss the suspected interaction between thienopyridines, particularly clopidogrel, and proton pump inhibitors (PPIs).
• To evaluate the impact of this interaction on platelet inhibition and cardiac event risk.

Main Methods:

• Review of existing literature on thienopyridines, P2Y12 inhibition, and PPIs.
• Analysis of pharmacokinetic and pharmacodynamic data for thienopyridine drugs.
• Critical evaluation of studies investigating drug-drug interactions between thienopyridines and PPIs.

Main Results:

• Thienopyridines are effective P2Y12 inhibitors used in cardiovascular disease management.
• A potential interaction exists between thienopyridines (especially clopidogrel) and PPIs.
• This interaction may reduce the antiplatelet effect of thienopyridines, potentially increasing cardiac event risk.

Conclusions:

• Understanding thienopyridine pharmacology is crucial for optimizing ACS and PCI patient care.
• The interaction between thienopyridines and PPIs warrants careful consideration to mitigate risks.
• Further research is needed to fully elucidate and manage this drug interaction.